CYYNF (Cynata Therapeutics) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2025)


What is Cynata Therapeutics DeferredTaxAndRevenue?

Cynata Therapeutics CYYNF DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cynata Therapeutics's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Cynata Therapeutics DeferredTaxAndRevenue Related Terms

Cynata Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Cynata Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics DeferredTaxAndRevenue Chart

Cynata Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cynata Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Cynata Therapeutics (CYYNF) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Cynata Therapeutics.
Is Cynata Therapeutics' DeferredTaxAndRevenue too high?
Cynata Therapeutics' current DeferredTaxAndRevenue is $0.00 Mil.
How does Cynata Therapeutics' DeferredTaxAndRevenue compare to VRTX and REGN?
Cynata Therapeutics' DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Cynata Therapeutics. Cynata Therapeutics's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.